EA029542B1 - ПРОИЗВОДНЫЕ 4Н-ПИРИДО[1,2-а]ПИРИМИДИН-4-ОНА ДЛЯ ЛЕЧЕНИЯ СПИНАЛЬНОЙ МЫШЕЧНОЙ АТРОФИИ - Google Patents

ПРОИЗВОДНЫЕ 4Н-ПИРИДО[1,2-а]ПИРИМИДИН-4-ОНА ДЛЯ ЛЕЧЕНИЯ СПИНАЛЬНОЙ МЫШЕЧНОЙ АТРОФИИ Download PDF

Info

Publication number
EA029542B1
EA029542B1 EA201491505A EA201491505A EA029542B1 EA 029542 B1 EA029542 B1 EA 029542B1 EA 201491505 A EA201491505 A EA 201491505A EA 201491505 A EA201491505 A EA 201491505A EA 029542 B1 EA029542 B1 EA 029542B1
Authority
EA
Eurasian Patent Office
Prior art keywords
pyrido
pyrimidin
pyrazin
methyl
pyrimidine
Prior art date
Application number
EA201491505A
Other languages
English (en)
Russian (ru)
Other versions
EA201491505A1 (ru
Inventor
Хунянь Ци
Соонгиу Чой
Амал Дакка
Гари Митчелл Карп
Яна Нарасимхан
Николай Нарышкин
Энтони А. Турпофф
Марла Л. Виталл
Эллен Уэлч
Мэттью Г. Волл
Тяньлэ Ян
Наньцзин Чжан
Сяоянь Чжан
Синь Чжао
Люк Грин
Эммануэль Пинар
Хасан Ратни
Original Assignee
ПиТиСи ТЕРАПЬЮТИКС, ИНК.
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48948163&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA029542(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ПиТиСи ТЕРАПЬЮТИКС, ИНК., Ф. Хоффманн-Ля Рош Аг filed Critical ПиТиСи ТЕРАПЬЮТИКС, ИНК.
Publication of EA201491505A1 publication Critical patent/EA201491505A1/ru
Publication of EA029542B1 publication Critical patent/EA029542B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
EA201491505A 2012-02-10 2013-02-08 ПРОИЗВОДНЫЕ 4Н-ПИРИДО[1,2-а]ПИРИМИДИН-4-ОНА ДЛЯ ЛЕЧЕНИЯ СПИНАЛЬНОЙ МЫШЕЧНОЙ АТРОФИИ EA029542B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261597523P 2012-02-10 2012-02-10
PCT/US2013/025292 WO2013119916A2 (en) 2012-02-10 2013-02-08 Compounds for treating spinal muscular atrophy

Publications (2)

Publication Number Publication Date
EA201491505A1 EA201491505A1 (ru) 2015-01-30
EA029542B1 true EA029542B1 (ru) 2018-04-30

Family

ID=48948163

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201792465A EA037123B1 (ru) 2012-02-10 2013-02-08 Соединения для лечения спинальной мышечной атрофии
EA201491505A EA029542B1 (ru) 2012-02-10 2013-02-08 ПРОИЗВОДНЫЕ 4Н-ПИРИДО[1,2-а]ПИРИМИДИН-4-ОНА ДЛЯ ЛЕЧЕНИЯ СПИНАЛЬНОЙ МЫШЕЧНОЙ АТРОФИИ

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201792465A EA037123B1 (ru) 2012-02-10 2013-02-08 Соединения для лечения спинальной мышечной атрофии

Country Status (29)

Country Link
US (6) US9586955B2 (OSRAM)
EP (2) EP3406252B1 (OSRAM)
JP (2) JP6092897B2 (OSRAM)
KR (2) KR102341596B1 (OSRAM)
CN (3) CN119528903A (OSRAM)
AR (1) AR092794A1 (OSRAM)
AU (2) AU2013216870B2 (OSRAM)
BR (1) BR112014019750B1 (OSRAM)
CA (1) CA2863874C (OSRAM)
CL (1) CL2014002100A1 (OSRAM)
CO (1) CO7061082A2 (OSRAM)
CR (1) CR20140376A (OSRAM)
DK (1) DK2812004T3 (OSRAM)
EA (2) EA037123B1 (OSRAM)
EC (1) ECSP14017269A (OSRAM)
ES (1) ES2697174T3 (OSRAM)
HU (1) HUE039779T2 (OSRAM)
IL (2) IL233959A (OSRAM)
MA (1) MA35920B1 (OSRAM)
MX (2) MX354074B (OSRAM)
NZ (1) NZ628186A (OSRAM)
PE (1) PE20142364A1 (OSRAM)
PH (2) PH12018501711B1 (OSRAM)
PL (1) PL2812004T3 (OSRAM)
SG (2) SG11201404713PA (OSRAM)
TR (1) TR201813877T4 (OSRAM)
TW (2) TWI585085B (OSRAM)
UA (1) UA116981C2 (OSRAM)
WO (1) WO2013119916A2 (OSRAM)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10327940B2 (en) 2008-11-09 2019-06-25 3D Systems, Inc. Spiral brace
USRE47689E1 (en) 2011-12-30 2019-11-05 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
PL2809322T3 (pl) 2012-01-26 2019-11-29 Ptc Therapeutics Inc Związki do leczenia zaniku mięśni pochodzenia rdzeniowego
CN119528903A (zh) 2012-02-10 2025-02-28 Ptc医疗公司 用于治疗脊髓性肌萎缩的化合物
CA2865957C (en) 2012-03-01 2020-02-11 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
KR102109992B1 (ko) 2012-03-23 2020-05-13 피티씨 테라퓨틱스, 인크. 척수성 근위축증을 치료하기 위한 화합물
US10987370B2 (en) * 2012-12-24 2021-04-27 Ramot At Tel-Aviv University Ltd. Methods of inducing read-through of a nonsense mutation associated with ataxia telangiectasia, Rett syndrome or spinal muscular atrophy by erythromycin or azithromycin
BR112015032718A2 (pt) 2013-08-19 2019-09-17 Hoffmann La Roche composto de modificação de splicing do gene foxm1, uso do composto, formulação farmacêutica e métodos de triagem de compostos
WO2015105657A1 (en) * 2013-12-19 2015-07-16 Ptc Therapeutics, Inc. Methods for modulating the amount of rna transcripts
PL3663296T3 (pl) * 2014-05-15 2023-08-07 F. Hoffmann-La Roche Ag Sposób wytwarzania związków użytecznych w leczeniu rdzeniowego zaniku mięśni
US10882868B2 (en) 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
US10436802B2 (en) 2014-09-12 2019-10-08 Biogen Ma Inc. Methods for treating spinal muscular atrophy
CN107109411B (zh) 2014-10-03 2022-07-01 冷泉港实验室 核基因输出的定向增加
ES2879809T3 (es) * 2014-11-01 2021-11-23 Shanghai Fochon Pharmaceutical Co Ltd Ciertos inhibidores de proteínas quinasas
WO2016111896A1 (en) * 2015-01-05 2016-07-14 Sikorsky Aircraft Corporation Integrated vibration damper for additively manufactured structure and method
JP6749343B2 (ja) * 2015-05-20 2020-09-02 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 脊髄性筋萎縮症を処置するための化合物
US10668171B2 (en) 2015-05-30 2020-06-02 Ptc Therapeutics, Inc. Methods for modulating RNA splicing
EP3359685A1 (en) 2015-10-09 2018-08-15 University Of Southampton Modulation of gene expression and screening for deregulated protein expression
CN108289959B (zh) 2015-11-12 2021-07-16 豪夫迈·罗氏有限公司 用于治疗脊髓性肌萎缩的组合物
KR20180081520A (ko) * 2015-11-12 2018-07-16 에프. 호프만-라 로슈 아게 근위축성 측삭 경화증의 치료를 위한 화합물
HRP20201522T1 (hr) 2015-12-09 2020-12-11 Cadent Therapeutics, Inc. Heteroaromatski nmda receptor modulatori i njihove uporabe
EA201800367A1 (ru) 2015-12-10 2019-02-28 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения болезни хантингтона
EP3386978B1 (en) 2015-12-10 2021-01-27 H. Hoffnabb-La Roche Ag Bridged piperidine derivatives
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
US11083745B2 (en) 2015-12-14 2021-08-10 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant mental retardation-5 and Dravet Syndrome
CN108473510B (zh) * 2016-04-28 2021-10-29 豪夫迈·罗氏有限公司 制备2-吡唑并[1,5-a]吡嗪-2-基吡啶并[1,2-a]嘧啶-4-酮的方法
EP3471779A4 (en) 2016-06-16 2020-07-08 Ionis Pharmaceuticals, Inc. COMBINATIONS FOR MODULATING SMN EXPRESSION
US11702646B2 (en) 2016-11-28 2023-07-18 Ptc Therapeutics, Inc. Methods for modulating RNA splicing
EP3558318B1 (en) 2016-12-22 2023-12-20 Novartis AG Nmda receptor modulators and uses thereof
KR20200033249A (ko) 2017-06-05 2020-03-27 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료 화합물
JP2020523365A (ja) 2017-06-14 2020-08-06 ピーティーシー セラピューティクス,インコーポレーテッド Rnaスプライシングを改変する方法
CA3067591A1 (en) * 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
US11395822B2 (en) 2017-06-28 2022-07-26 Ptc Therapeutics, Inc. Methods for treating Huntington's disease
CN111499615B (zh) 2017-08-04 2024-02-02 斯基霍克疗法公司 用于调节剪接的方法和组合物
SMT202400071T1 (it) 2017-08-25 2024-03-13 Stoke Therapeutics Inc Oligomeri antisenso per il trattamento di condizioni e malattie
MX2020002711A (es) * 2017-09-22 2020-07-20 Hoffmann La Roche Proceso para preparacion de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-( 2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4- ona.
HRP20250322T1 (hr) 2017-10-23 2025-06-06 Stoke Therapeutics, Inc. Protusmisleni oligomeri, namijenjeni liječenju stanja i bolesti uzrokovanih raspadanjem rna posredovanim besmislenim mutacijama
US12103926B2 (en) 2018-03-27 2024-10-01 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
JP2021523227A (ja) 2018-05-04 2021-09-02 ストーク セラピューティクス,インク. コレステリルエステル蓄積症の処置のための方法及び組成物
SG11202013088YA (en) 2018-06-27 2021-02-25 Reborna Biosciences Inc Prophylactic or therapeutic agent for spinal muscular atrophy
EA202092899A1 (ru) 2018-06-27 2021-05-14 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Гетероарильные соединения для лечения болезни гентингтона
BR112020026545A2 (pt) 2018-06-27 2021-03-23 Ptc Therapeutics, Inc. Compostos heterocíclicos e de heteroarila para o tratamento da doença de huntington
EP3814360B8 (en) 2018-06-27 2024-11-06 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
CU24647B1 (es) 2018-08-03 2023-02-13 Cadent Therapeutics Inc Moduladores del receptor nmda heteroaromático
KR20210042123A (ko) * 2018-08-07 2021-04-16 더 칠드런스 호스피탈 오브 필라델피아 유전자 발현의 선택적 스플라이싱 조절 및 치료 방법
CN114007613A (zh) 2019-02-05 2022-02-01 斯基霍克疗法公司 用于调节剪接的方法和组合物
JP7603595B2 (ja) 2019-02-06 2024-12-20 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
US11129829B2 (en) 2019-06-17 2021-09-28 Skyhawk Therapeutics, Inc. Methods for modulating splicing
US12492214B2 (en) 2019-07-31 2025-12-09 Assia Chemical Industries Ltd. Solid state forms of Risdiplam and process for preparation thereof
CN110540535B (zh) * 2019-10-23 2020-07-31 上海再启生物技术有限公司 适合放大制备4-(6-氨基吡啶-3-基)取代哌啶的工艺方法
CN111116576A (zh) * 2019-12-01 2020-05-08 北京师范大学 一种喹嗪酮类化合物及其制备方法
BR112022010561A2 (pt) 2019-12-02 2022-11-16 Storm Therapeutics Ltd Compostos poli-heterocíclicos como inibidores de mettl3
MX2022009025A (es) 2020-01-28 2022-10-07 Protego Biopharma Inc Compuestos, composiciones y métodos para estabilizar la transtiretina e inhibir el plegamiento incorrecto de la transtiretina.
EP4103717A4 (en) * 2020-02-12 2024-02-28 The Children's Hospital of Philadelphia Compositions and methods for inducible alternative splicing regulation of gene expression
EP4110775A1 (en) 2020-02-28 2023-01-04 Remix Therapeutics Inc. Thiophenyl derivatives useful for modulating nucleic acid splicing
MX2022010634A (es) 2020-02-28 2023-01-19 Remix Therapeutics Inc Derivados de piridazina para modular el empalme de acidos nucleicos.
JP7446443B2 (ja) 2020-02-28 2024-03-08 アイオーニス ファーマシューティカルズ, インコーポレーテッド Smn2を調節するための化合物及び方法
JP7736700B2 (ja) 2020-02-28 2025-09-09 リミックス セラピューティクス インコーポレイテッド 複素環アミド及びスプライシングを調節するためのその使用
AU2021228285A1 (en) 2020-02-28 2022-09-29 Remix Therapeutics Inc. Compounds and methods for modulating splicing
TW202208344A (zh) 2020-04-08 2022-03-01 美商雷密克斯醫療公司 調節剪接之化合物及方法
BR112022020418A2 (pt) 2020-04-08 2023-05-02 Remix Therapeutics Inc Compostos e métodos para modulação de splicing
CA3173647A1 (en) 2020-05-11 2021-11-18 Isabel AZNAREZ Opa1 antisense oligomers for treatment of conditions and diseases
WO2022006543A1 (en) 2020-07-02 2022-01-06 Remix Therapeutics Inc. 5-[5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
WO2022006550A1 (en) 2020-07-02 2022-01-06 Remix Therapeutics Inc. 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
WO2022070071A1 (en) * 2020-09-30 2022-04-07 Janssen Biotech, Inc. Dihydroorotate dehydrogenase inhibitors
KR20230157367A (ko) 2021-03-17 2023-11-16 에프. 호프만-라 로슈 아게 신규 티아졸로피리미디논 유도체
TW202321206A (zh) 2021-07-28 2023-06-01 美商普羅泰戈生物製藥股份有限公司 轉甲狀腺素蛋白穩定化合物
WO2023034827A1 (en) 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
US20240400584A1 (en) 2021-08-30 2024-12-05 Remix Therapeutics Inc. Compounds and methods for modulating splicing
PE20241764A1 (es) 2021-08-30 2024-08-28 Remix Therapeutics Inc Compuestos y metodos para modular el empalme
WO2023034836A1 (en) 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
TW202319047A (zh) 2021-08-30 2023-05-16 美商雷密克斯醫療公司 調節剪接之化合物及用途
EP4416141A1 (en) 2021-10-13 2024-08-21 Remix Therapeutics Inc. Compounds and methods for modulating nucleic acid splicing
WO2023064879A1 (en) 2021-10-13 2023-04-20 Remix Therapeutics Inc. Compounds and methods for modulating nucleic acid splicing
US20250109140A1 (en) 2022-01-05 2025-04-03 Remix Theraputics Inc. 5-[5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
US20250092065A1 (en) 2022-01-05 2025-03-20 Remix Therapeutics Inc. 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
US20250326748A1 (en) 2022-01-05 2025-10-23 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2023240236A1 (en) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of spinal muscular atrophy related disorders
AU2024286618A1 (en) * 2023-06-09 2025-10-30 F. Hoffmann-La Roche Ag Inducible gene expression system
CN117263936B (zh) * 2023-11-21 2024-02-23 中国中医科学院医学实验中心 一种咪唑并[1, 2-a]吡啶衍生物及其制备方法和在中枢神经系统渗透性HDAC6抑制药物中的应用
WO2025233837A1 (en) 2024-05-07 2025-11-13 Takeda Pharmaceutical Company Limited 4h-pyrimido[1,2-a]pyrimidin-4-one derivatives for use as nlrp3 inflammasome inhibitors for the treatment of neurodegenerative disorder

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558618A (en) * 1968-04-01 1971-01-26 Dow Chemical Co Novel 4h-pyrazino(1,2-a)pyrimidine-4-ones
US4122274A (en) * 1977-05-25 1978-10-24 Bristol-Myers Company 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones
US4342870A (en) * 1980-03-28 1982-08-03 Janssen Pharmaceutica N.V. Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives
WO1993023398A1 (en) * 1992-05-13 1993-11-25 E.I. Du Pont De Nemours And Company Substituted pyrido[1,2-a]pyrimidinone derivatives as fungicides
US5599816A (en) * 1990-05-02 1997-02-04 Abbott Laboratories Quinolizinone type compounds
US6630488B1 (en) * 1998-09-21 2003-10-07 Biochem Pharma, Inc. Quinolizinones as integrin inhibitors
US6977255B2 (en) * 2000-01-24 2005-12-20 Kinacia Pty. Ltd. Therapeutic morpholino-substituted compounds
US7326711B2 (en) * 2003-06-20 2008-02-05 Chiron Corporation Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents
US20080255162A1 (en) * 2004-05-04 2008-10-16 Warner-Lambert Company Llc Pyrrolyl Substituted Pyrido[2,3-D]Pyrimidin-7-Ones and Derivatives Thereof as Therapeutic Agents
WO2011062853A1 (en) * 2009-11-20 2011-05-26 Merck Sharp & Dohme Corp. Quinolizidinone carboxamide m1 receptor positive allosteric modulators
WO2011085990A1 (en) * 2010-01-13 2011-07-21 Institut Pasteur Korea Anti - infective pyrido (1,2 -a) pyrimidines

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56150091A (en) * 1980-03-28 1981-11-20 Janssen Pharmaceutica Nv 3-(1-piperidinylalkyl)-4h-pyrido(1,2-a)pyrimidine- 4-one derivative and its manufacture
US5089633A (en) 1987-04-28 1992-02-18 Georgia Tech Research Corporation Substituted isocoumarins
WO1996039407A1 (en) 1995-06-06 1996-12-12 Abbott Laboratories Quinolizinone type compounds
US5869500A (en) 1996-12-13 1999-02-09 Hoffmann-La Roche Inc. Pyridone compounds useful in treating Alzheimer's disease
DE60024861T2 (de) * 1999-10-28 2006-07-06 Trine Pharmaceuticals, Inc., Waltham Pumpeninhibitoren zur freisetzung von medikamenten
CA2445697A1 (en) 2001-04-26 2002-11-07 Daiichi Pharmaceutical Co., Ltd. Drug efflux pump inhibitor
DE60236322D1 (de) 2001-12-07 2010-06-17 Vertex Pharma Verbindungen auf pyrimidin-basis als gsk-3-hemmer
GB0205281D0 (en) 2002-03-06 2002-04-17 Novartis Ag Organic compounds
ATE548354T1 (de) 2002-07-24 2012-03-15 Ptc Therapeutics Inc Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
CN101146798A (zh) 2005-01-21 2008-03-19 詹森药业有限公司 用作雌激素受体调节剂的新的杂环苯并[c]色烯衍生物
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
US8110681B2 (en) * 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
WO2008013997A2 (en) 2006-07-27 2008-01-31 The Trustees Of Columbia University In The City Of New York Fluorescent substrates for monoamine transporters as optical false neurotransmitters
WO2009151546A2 (en) 2008-05-27 2009-12-17 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
EP2138493A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted pyrimidone derivatives
US8932818B2 (en) 2008-08-13 2015-01-13 Ptc Therapeutics, Inc. Screening assays for compounds that modulate programmed ribosomal frameshifting
WO2011050245A1 (en) * 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
USRE47689E1 (en) 2011-12-30 2019-11-05 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
PL2809322T3 (pl) 2012-01-26 2019-11-29 Ptc Therapeutics Inc Związki do leczenia zaniku mięśni pochodzenia rdzeniowego
CN119528903A (zh) * 2012-02-10 2025-02-28 Ptc医疗公司 用于治疗脊髓性肌萎缩的化合物
CA2865957C (en) 2012-03-01 2020-02-11 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
KR102109992B1 (ko) 2012-03-23 2020-05-13 피티씨 테라퓨틱스, 인크. 척수성 근위축증을 치료하기 위한 화합물
PL3663296T3 (pl) 2014-05-15 2023-08-07 F. Hoffmann-La Roche Ag Sposób wytwarzania związków użytecznych w leczeniu rdzeniowego zaniku mięśni
JP6749343B2 (ja) 2015-05-20 2020-09-02 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 脊髄性筋萎縮症を処置するための化合物

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558618A (en) * 1968-04-01 1971-01-26 Dow Chemical Co Novel 4h-pyrazino(1,2-a)pyrimidine-4-ones
US4122274A (en) * 1977-05-25 1978-10-24 Bristol-Myers Company 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones
US4342870A (en) * 1980-03-28 1982-08-03 Janssen Pharmaceutica N.V. Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives
US5599816A (en) * 1990-05-02 1997-02-04 Abbott Laboratories Quinolizinone type compounds
WO1993023398A1 (en) * 1992-05-13 1993-11-25 E.I. Du Pont De Nemours And Company Substituted pyrido[1,2-a]pyrimidinone derivatives as fungicides
US6630488B1 (en) * 1998-09-21 2003-10-07 Biochem Pharma, Inc. Quinolizinones as integrin inhibitors
US6977255B2 (en) * 2000-01-24 2005-12-20 Kinacia Pty. Ltd. Therapeutic morpholino-substituted compounds
US7326711B2 (en) * 2003-06-20 2008-02-05 Chiron Corporation Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents
US20080255162A1 (en) * 2004-05-04 2008-10-16 Warner-Lambert Company Llc Pyrrolyl Substituted Pyrido[2,3-D]Pyrimidin-7-Ones and Derivatives Thereof as Therapeutic Agents
WO2011062853A1 (en) * 2009-11-20 2011-05-26 Merck Sharp & Dohme Corp. Quinolizidinone carboxamide m1 receptor positive allosteric modulators
WO2011085990A1 (en) * 2010-01-13 2011-07-21 Institut Pasteur Korea Anti - infective pyrido (1,2 -a) pyrimidines

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Jarecki, et al. Diverse smal1-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy. Human Molecular Genetics 2005, 14(14):2003-2018; abstract, Fig. 7 *
Knight, et al. Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorganic & Medicinal Chemistry 2004, 12:4749-4759; pg. 4752, Fig. 2A *
Kocar, et al. Transformations of 3-aminopyridazines. Synthesis of 4-oxo-4H-pyrimido[1,2-b]pyridazine and 1-(substituted pyridazin-3-yl)-1H-1,2,3-triazole derivatives. ARKIVOC 2002 (viii) 143-156. [Retrieved from the Internet July 2013: <http://www.arkat-usa.org/get-file.php?fileid=20004>]; pg. 145-146, Scheme 1 *
Makhortova, et al. A Screen for Regulators of Survival of Motor Neuron Protein Levels. Nat Chem Biol 2011, 7(8):544-552; whole doc. *
PubChem compoudn CID 377422. 26 March 2005. [Retrieved from the Internet 28 March 2013: <http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=377422>] *

Also Published As

Publication number Publication date
JP2017122097A (ja) 2017-07-13
HUE039779T2 (hu) 2019-02-28
IL254045B (en) 2019-05-30
US20240067646A1 (en) 2024-02-29
EA201792465A1 (ru) 2018-08-31
BR112014019750A8 (pt) 2018-01-16
MX2022011699A (es) 2022-11-09
AR092794A1 (es) 2015-05-06
JP6363744B2 (ja) 2018-07-25
EP3406252A1 (en) 2018-11-28
KR20200093066A (ko) 2020-08-04
PE20142364A1 (es) 2015-01-10
IL254045A0 (en) 2017-10-31
AU2013216870B2 (en) 2017-07-20
PH12018501711A1 (en) 2019-09-23
TWI585085B (zh) 2017-06-01
AU2013216870A1 (en) 2014-08-28
IL233959A (en) 2017-11-30
EP2812004B1 (en) 2018-06-27
EP2812004A4 (en) 2015-11-11
NZ628186A (en) 2016-03-31
CN104349777B (zh) 2018-05-01
US20180105526A1 (en) 2018-04-19
EP2812004A2 (en) 2014-12-17
US20170129885A1 (en) 2017-05-11
CO7061082A2 (es) 2014-09-19
BR112014019750B1 (pt) 2020-03-03
MX354074B (es) 2018-02-12
US9879007B2 (en) 2018-01-30
PH12014501786A1 (en) 2014-11-10
AU2017204248B2 (en) 2019-05-30
PH12018501711B1 (en) 2023-05-05
US20150005289A1 (en) 2015-01-01
ECSP14017269A (es) 2015-09-30
EP3406252B1 (en) 2020-05-13
TW201336842A (zh) 2013-09-16
CR20140376A (es) 2015-01-23
IL233959A0 (en) 2014-09-30
JP6092897B2 (ja) 2017-03-08
SG10201609188WA (en) 2016-12-29
US20190375750A1 (en) 2019-12-12
CN108299314A (zh) 2018-07-20
MX2014009696A (es) 2015-01-14
UA116981C2 (uk) 2018-06-11
TW201722942A (zh) 2017-07-01
JP2015508075A (ja) 2015-03-16
WO2013119916A3 (en) 2013-10-24
CA2863874C (en) 2021-02-16
KR20140121482A (ko) 2014-10-15
TWI629274B (zh) 2018-07-11
US20210276999A1 (en) 2021-09-09
ES2697174T3 (es) 2019-01-22
DK2812004T3 (en) 2018-10-15
CA2863874A1 (en) 2013-08-15
CL2014002100A1 (es) 2015-10-23
TR201813877T4 (tr) 2018-11-21
AU2017204248A1 (en) 2017-07-13
US11753407B2 (en) 2023-09-12
WO2013119916A2 (en) 2013-08-15
EA201491505A1 (ru) 2015-01-30
HK1202077A1 (en) 2015-09-18
CN119528903A (zh) 2025-02-28
BR112014019750A2 (pt) 2017-06-20
MA35920B1 (fr) 2014-12-01
PL2812004T3 (pl) 2019-01-31
KR102341596B1 (ko) 2021-12-21
CN104349777A (zh) 2015-02-11
US10851101B2 (en) 2020-12-01
US9586955B2 (en) 2017-03-07
SG11201404713PA (en) 2014-09-26
EA037123B1 (ru) 2021-02-09
CN108299314B (zh) 2024-11-26
PH12014501786B1 (en) 2014-11-10
KR102137087B1 (ko) 2020-07-24

Similar Documents

Publication Publication Date Title
US20240067646A1 (en) Compounds for treating spinal muscular atrophy
EA029984B1 (ru) Соединения для лечения спинальной мышечной атрофии
BR112014016443B1 (pt) Mistura de pó e método de fabricação de um componente sinterizado
HK40005163A (en) Compounds for treating spinal muscular atrophy
HK40005163B (en) Compounds for treating spinal muscular atrophy
HK1202077B (en) Compounds for treating spinal muscular atrophy
HK1202059B (en) Compounds for treating spinal muscular atrophy

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM